Do analysts rate FARN or AVCT?

Avacta Group has a consensus target price of GBX 99, indicating a potential upside of 47.76%. Given Avacta Group's stronger consensus rating and higher possible upside, analysts plainly believe Avacta Group is more favorable than Faron Pharmaceuticals Oy. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Faron Pharmaceuticals Oy 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Avacta Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Does the media refer more to FARN or AVCT?

In the previous week, Faron Pharmaceuticals Oy and Faron Pharmaceuticals Oy both had 1 articles in the media. Faron Pharmaceuticals Oy's average media sentiment score of 0.75 beat Avacta Group's score of 0.67 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Faron Pharmaceuticals Oy 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avacta Group 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is FARN or HZD more profitable?

Faron Pharmaceuticals Oy's return on equity of 45.13% beat Horizon Discovery Group plc (HZD.L)'s return on equity. Company Net Margins Return on Equity Return on Assets Faron Pharmaceuticals Oy N/A 45.13% -70.00% Horizon Discovery Group plc (HZD.L) N/A N/A N/A

Do analysts rate PRTC or FARN?

PureTech Health currently has a consensus target price of GBX 508, suggesting a potential upside of 331.97%. Given PureTech Health's stronger consensus rating and higher probable upside, analysts plainly believe PureTech Health is more favorable than Faron Pharmaceuticals Oy. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Faron Pharmaceuticals Oy 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media prefer PRTC or FARN?

In the previous week, PureTech Health and PureTech Health both had 1 articles in the media. PureTech Health's average media sentiment score of 1.11 beat Faron Pharmaceuticals Oy's score of 0.75 indicating that PureTech Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PureTech Health 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Faron Pharmaceuticals Oy 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CIR or FARN more profitable?

Faron Pharmaceuticals Oy's return on equity of 45.13% beat Circassia Group's return on equity. Company Net Margins Return on Equity Return on Assets Circassia Group N/A N/A N/A Faron Pharmaceuticals Oy N/A 45.13% -70.00%

Faron Pharmaceuticals Oy (FARN) Competitors

GBX 40.11 -0.39 (-0.96%)

As of 08/21/2026 11:42 AM Eastern

Compare

FARN vs. AVCT, HZD, PRTC, ARIX, and CIR

Should you buy Faron Pharmaceuticals Oy stock or one of its competitors? Faron Pharmaceuticals Oy's main competitors and comparable companies include Avacta Group (AVCT), Horizon Discovery Group plc (HZD.L) (HZD), PureTech Health (PRTC), Arix Bioscience (ARIX), and Circassia Group (CIR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Faron Pharmaceuticals Oy compare to Avacta Group?

Faron Pharmaceuticals Oy (LON:FARN) and Avacta Group (LON:AVCT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

Faron Pharmaceuticals Oy has a beta of 1.121, meaning that its share price is 12% more volatile than the broader market. Comparatively, Avacta Group has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

Avacta Group has higher revenue and earnings than Faron Pharmaceuticals Oy. Avacta Group is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£22.07	N/A
Avacta Group	£113K	2,778.12	-£30.08M	-£9.66	N/A

Faron Pharmaceuticals Oy has a net margin of 0.00% compared to Avacta Group's net margin of -33,961.06%. Faron Pharmaceuticals Oy's return on equity of 45.13% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Faron Pharmaceuticals Oy	N/A	45.13%	-70.00%
Avacta Group	-33,961.06%	-2,929.47%	-21.80%

1.6% of Faron Pharmaceuticals Oy shares are owned by institutional investors. Comparatively, 3.1% of Avacta Group shares are owned by institutional investors. 2.7% of Faron Pharmaceuticals Oy shares are owned by insiders. Comparatively, 47.7% of Avacta Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Faron Pharmaceuticals Oy and Faron Pharmaceuticals Oy both had 1 articles in the media. Faron Pharmaceuticals Oy's average media sentiment score of 0.75 beat Avacta Group's score of 0.67 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Faron Pharmaceuticals Oy	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avacta Group	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avacta Group has a consensus target price of GBX 99, indicating a potential upside of 47.76%. Given Avacta Group's stronger consensus rating and higher possible upside, analysts plainly believe Avacta Group is more favorable than Faron Pharmaceuticals Oy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Faron Pharmaceuticals Oy	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Avacta Group beats Faron Pharmaceuticals Oy on 9 of the 14 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to Horizon Discovery Group plc (HZD.L)?

Faron Pharmaceuticals Oy (LON:FARN) and Horizon Discovery Group plc (HZD.L) (LON:HZD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

Horizon Discovery Group plc (HZD.L) has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Horizon Discovery Group plc (HZD.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£22.07	N/A
Horizon Discovery Group plc (HZD.L)	£54.63M	0.00	N/A	-£5.50	N/A

Faron Pharmaceuticals Oy's return on equity of 45.13% beat Horizon Discovery Group plc (HZD.L)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Faron Pharmaceuticals Oy	N/A	45.13%	-70.00%
Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A

In the previous week, Faron Pharmaceuticals Oy had 1 more articles in the media than Horizon Discovery Group plc (HZD.L). MarketBeat recorded 1 mentions for Faron Pharmaceuticals Oy and 0 mentions for Horizon Discovery Group plc (HZD.L). Faron Pharmaceuticals Oy's average media sentiment score of 0.75 beat Horizon Discovery Group plc (HZD.L)'s score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media.

Company	Overall Sentiment
Faron Pharmaceuticals Oy	Positive
Horizon Discovery Group plc (HZD.L)	Neutral

1.6% of Faron Pharmaceuticals Oy shares are owned by institutional investors. 2.7% of Faron Pharmaceuticals Oy shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Faron Pharmaceuticals Oy beats Horizon Discovery Group plc (HZD.L) on 6 of the 9 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to PureTech Health?

PureTech Health (LON:PRTC) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

Faron Pharmaceuticals Oy has lower revenue, but higher earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£4.66M	61.44	-£91.86M	-£46.00	N/A
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£22.07	N/A

Faron Pharmaceuticals Oy has a net margin of 0.00% compared to PureTech Health's net margin of -2,355.32%. Faron Pharmaceuticals Oy's return on equity of 45.13% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	-2,355.32%	-31.98%	-13.39%
Faron Pharmaceuticals Oy	N/A	45.13%	-70.00%

PureTech Health has a beta of 0.771, suggesting that its share price is 23% less volatile than the broader market. Comparatively, Faron Pharmaceuticals Oy has a beta of 1.121, suggesting that its share price is 12% more volatile than the broader market.

In the previous week, PureTech Health and PureTech Health both had 1 articles in the media. PureTech Health's average media sentiment score of 1.11 beat Faron Pharmaceuticals Oy's score of 0.75 indicating that PureTech Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PureTech Health	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Faron Pharmaceuticals Oy	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PureTech Health currently has a consensus target price of GBX 508, suggesting a potential upside of 331.97%. Given PureTech Health's stronger consensus rating and higher probable upside, analysts plainly believe PureTech Health is more favorable than Faron Pharmaceuticals Oy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Faron Pharmaceuticals Oy	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

32.5% of PureTech Health shares are held by institutional investors. Comparatively, 1.6% of Faron Pharmaceuticals Oy shares are held by institutional investors. 13.4% of PureTech Health shares are held by company insiders. Comparatively, 2.7% of Faron Pharmaceuticals Oy shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

PureTech Health beats Faron Pharmaceuticals Oy on 8 of the 14 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to Arix Bioscience?

Arix Bioscience (LON:ARIX) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

In the previous week, Faron Pharmaceuticals Oy had 1 more articles in the media than Arix Bioscience. MarketBeat recorded 1 mentions for Faron Pharmaceuticals Oy and 0 mentions for Arix Bioscience. Faron Pharmaceuticals Oy's average media sentiment score of 0.75 beat Arix Bioscience's score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the news media.

Company	Overall Sentiment
Arix Bioscience	Neutral
Faron Pharmaceuticals Oy	Positive

41.3% of Arix Bioscience shares are owned by institutional investors. Comparatively, 1.6% of Faron Pharmaceuticals Oy shares are owned by institutional investors. 20.7% of Arix Bioscience shares are owned by insiders. Comparatively, 2.7% of Faron Pharmaceuticals Oy shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Arix Bioscience has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, Faron Pharmaceuticals Oy has a beta of 1.121, indicating that its share price is 12% more volatile than the broader market.

Arix Bioscience has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arix Bioscience	£14.16M	0.00	£14.96M	£0.11	N/A
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£22.07	N/A

Arix Bioscience has a net margin of 105.64% compared to Faron Pharmaceuticals Oy's net margin of 0.00%. Faron Pharmaceuticals Oy's return on equity of 45.13% beat Arix Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arix Bioscience	105.64%	6.41%	2.18%
Faron Pharmaceuticals Oy	N/A	45.13%	-70.00%

Summary

Arix Bioscience beats Faron Pharmaceuticals Oy on 8 of the 12 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to Circassia Group?

Circassia Group (LON:CIR) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

Faron Pharmaceuticals Oy's return on equity of 45.13% beat Circassia Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Circassia Group	N/A	N/A	N/A
Faron Pharmaceuticals Oy	N/A	45.13%	-70.00%

In the previous week, Faron Pharmaceuticals Oy had 1 more articles in the media than Circassia Group. MarketBeat recorded 1 mentions for Faron Pharmaceuticals Oy and 0 mentions for Circassia Group. Faron Pharmaceuticals Oy's average media sentiment score of 0.75 beat Circassia Group's score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the news media.

Company	Overall Sentiment
Circassia Group	Neutral
Faron Pharmaceuticals Oy	Positive

1.6% of Faron Pharmaceuticals Oy shares are held by institutional investors. 2.7% of Faron Pharmaceuticals Oy shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Circassia Group has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Circassia Group	£27.90M	0.00	N/A	£0.01	N/A
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£22.07	N/A

Summary

Faron Pharmaceuticals Oy beats Circassia Group on 5 of the 9 factors compared between the two stocks.

Get Faron Pharmaceuticals Oy News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FARN vs. The Competition

Export

Metric	Faron Pharmaceuticals Oy	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£83.18M	£4.01B	£7.38B	£2.54B
Dividend Yield	N/A	3.64%	2.53%	6.17%
P/E Ratio	-1.82	11.62	272.60	367.57
Price / Sales	N/A	1,334.62	623.33	83,481.74
Price / Cash	20.00	105.14	78.62	27.89
Price / Book	0.02	16.80	13.05	7.19
Net Income	-£60.23M	-£12.50M	£3.47B	£5.89B
7 Day Performance	1.29%	3.29%	2.09%	0.30%
1 Month Performance	-2.17%	8.23%	6.64%	3.31%
1 Year Performance	-81.89%	55.05%	25.02%	22.13%

Faron Pharmaceuticals Oy Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FARN Faron Pharmaceuticals Oy	N/A	GBX 40.11 -1.0%	N/A	-81.9%	£83.18M	N/A	N/A	34	News Coverage Gap Up
AVCT Avacta Group	2.4394 of 5 stars	GBX 67 -2.2%	GBX 99 +47.8%	+38.0%	£318.61M	£113K	N/A	120	News Coverage
HZD Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A	N/A	£302.98M	£54.63M	N/A	416
PRTC PureTech Health	3.6134 of 5 stars	GBX 117.60 +0.7%	GBX 508 +332.0%	-15.2%	£286.26M	£4.66M	N/A	300
ARIX Arix Bioscience	N/A	N/A	N/A	N/A	£183.73M	£14.16M	1,290.91	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:FARN) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Faron Pharmaceuticals Oy (FARN) Competitors

FARN vs. AVCT, HZD, PRTC, ARIX, and CIR

How does Faron Pharmaceuticals Oy compare to Avacta Group?

Summary

How does Faron Pharmaceuticals Oy compare to Horizon Discovery Group plc (HZD.L)?

Summary

How does Faron Pharmaceuticals Oy compare to PureTech Health?

Summary

How does Faron Pharmaceuticals Oy compare to Arix Bioscience?

Summary

How does Faron Pharmaceuticals Oy compare to Circassia Group?

Summary

Media Sentiment Over Time

FARN vs. The Competition

Faron Pharmaceuticals Oy Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Faron Pharmaceuticals Oy (FARN) Competitors

FARN vs. AVCT, HZD, PRTC, ARIX, and CIR

How does Faron Pharmaceuticals Oy compare to Avacta Group?

Which has more volatility and risk, FARN or AVCT?

Which has preferable valuation and earnings, FARN or AVCT?

Is FARN or AVCT more profitable?

Do insiders & institutionals have more ownership in FARN or AVCT?

Does the media refer more to FARN or AVCT?

Do analysts rate FARN or AVCT?

Summary

How does Faron Pharmaceuticals Oy compare to Horizon Discovery Group plc (HZD.L)?

Which has preferable earnings & valuation, FARN or HZD?

Is FARN or HZD more profitable?

Does the media prefer FARN or HZD?

Do institutionals & insiders believe in FARN or HZD?

Summary

How does Faron Pharmaceuticals Oy compare to PureTech Health?

Which has higher valuation and earnings, PRTC or FARN?

Is PRTC or FARN more profitable?

Which has more volatility and risk, PRTC or FARN?

Does the media prefer PRTC or FARN?

Do analysts rate PRTC or FARN?

Do insiders & institutionals believe in PRTC or FARN?

Summary

How does Faron Pharmaceuticals Oy compare to Arix Bioscience?

Does the media prefer ARIX or FARN?

Do institutionals and insiders believe in ARIX or FARN?

Which has more volatility & risk, ARIX or FARN?

Which has better earnings & valuation, ARIX or FARN?

Is ARIX or FARN more profitable?

Summary

How does Faron Pharmaceuticals Oy compare to Circassia Group?

Is CIR or FARN more profitable?

Does the media prefer CIR or FARN?

Do institutionals and insiders hold more shares of CIR or FARN?

Which has better earnings and valuation, CIR or FARN?

Summary

Media Sentiment Over Time

FARN vs. The Competition

Faron Pharmaceuticals Oy Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools